Showing 461 - 480 results of 224,747 for search '(( 50 ((we decrease) OR (teer decrease)) ) OR ( 10 ((nn decrease) OR (a decrease)) ))', query time: 1.58s Refine Results
  1. 461

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  2. 462

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  3. 463
  4. 464

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  5. 465
  6. 466
  7. 467
  8. 468
  9. 469
  10. 470
  11. 471
  12. 472
  13. 473
  14. 474
  15. 475
  16. 476
  17. 477

    Resveratrol Prevents Oxidative Stress-Induced Senescence and Proliferative Dysfunction by Activating the AMPK-FOXO3 Cascade in Cultured Primary Human Keratinocytes by Yasuo Ido (172159)

    Published 2015
    “…Resveratrol’s effects on both senescence and proliferation disappeared when FOXO3 was knocked down. Finally, we performed an exploratory study which showed that skin from humans over 50 years old had lower AMPK activity than skin from individuals under age 20. …”
  18. 478
  19. 479

    S1 Dataset - by Nelmo Jordão Manjate (16324619)

    Published 2023
    “…For diagnosis by nasal Ag-RDTs, Panbio was MZN 547.00 (USD 8.90), COVIOS was MZN 768.00 (USD 12.50), and LumiraDx was MZN 798.00 (USD 13.00). Medical supplies expenditures represented the main driver of the final cost (>50%), followed by personnel and overhead costs (mean 15% for each). …”
  20. 480